• Zijun Wang, Frauke Muecksch, Dennis Schaefer-Babajew, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Hans- Heinrich Hoffmann, Christopher O Barnes, Melissa Cipolla, Victor Ramos, Thiago Y Oliveira, Alice Cho, Fabian Schmidt, Justin Da Silva, Eva Bednarski, Lauren Aguado, Jim Yee, Mridushi Daga, Martina Turroja, Katrina G Millard, Mila Jankovic, Anna Gazumyan, Zhen Zhao, Charles M Rice, Paul D Bieniasz, Marina Caskey, Theodora Hatziioannou, and Michel C Nussenzweig.
• Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
• Nature. 2021 Jul 1; 595 (7867): 426-431.

AbstractMore than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies1,2. Here we report on a cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 and 12 months after SARS-CoV-2 infection, 41% of whom also received mRNA vaccines3,4. In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable between 6 and 12 months after infection. Vaccination increases all components of the humoral response and, as expected, results in serum neutralizing activities against variants of concern similar to or greater than the neutralizing activity against the original Wuhan Hu-1 strain achieved by vaccination of naive individuals2,5-8. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in the variants of concern4,9. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand markedly after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.© 2021. The Author(s).

32 keywords...

hide…